Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 419-426

  Haber, D A ^a   Bell, D W ^a   Sordella, R ^a   Kwak, E L ^a   Godin Heymann, N ^a   Sharma, S V ^a   Lynch, T J ^a   Settleman, J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADENOCARCINOMA; ASIAN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOWNSTREAM PROCESSING; DRUG RESISTANCE; ETHNOLOGY; HUMAN; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; SOLID TUMOR; SOMATIC MUTATION; ARTICLE; CELL MIGRATION; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MALE; MODELS, MOLECULAR; MUTATION; ONCOGENES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746418392     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.043     Document Type: Conference Paper

References (21)

1. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., Sgroi D.C., Muir B., Riemenschneider M.J., Iacona R.B., Krebs A.D., Johnson D.H., Giaccone G., Herbst R.S., Manegold C., Fukuoka M., Kris M.G., Baselga J., Ochs J.S., and Haber D.A. 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23: 8081.
2. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., Oh D.Y., Kim J.H., Kim D.W., Chung D.H., Im S.A., Kim Y.T., Lee J.S., Heo D.S., Bang Y.J., and Kim N.K. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23: 2493.
3. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., Bunn P.A., Jr., Franklin W.A., Crowley J., and Gandara D.R. (Southwest Oncology Group). 2005. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J. Clin. Oncol. 23: 6838.
4. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352: 786.
5. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Jr., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., and Kay A.C. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J. Am. Med. Assoc. 290: 2149.
6. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. 102: 7665.
7. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129.
8. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., and Mischel P.S. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353: 2012.
9. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., and Yatabe Y. 2005. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23: 2513.
10. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497.
11. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med. 3: e73.
12. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. 101: 13306.
13. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.R., Wang Y.F., and Wissner A. 2004. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64: 3958.
14. Riemenschneider M.J., Bell D.W., Haber D.A., and Louis D.N. 2005. Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. N. Engl. J. Med. 352: 1724.
15. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399.
16. Sharma S.V., Fischbach M.A., Haber D.A., and Settleman J. 2006. Oncogenic shock: Explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. (in press).
17. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., and Seymour L. (National Cancer Institute of Canada Clinical Trials Group). 2005. Erlotinib in previously treated non-smallcell lung cancer. N. Engl. J. Med. 353: 123.
18. Sordella R., Bell D.W., Haber D.A., and Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163.
19. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J., and Shepherd F.A. 2005. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N. Engl. J. Med. 353: 133.
20. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. 2002. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62: 5749.
21. Weinstein I.B. 2002. Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 297: 63.